engleski

Neuroprotection and treatment of acute ischemic stroke

Acute ischemic stroke is one of the major causes of mortality and long-term disability in both developed and developing countries of the world. lntravenous tissue plasminogen activator and mechanical thrombectomy are basic standards of treatment for acute ischemic stroke although not ideal for various restrictions and complications, limiting to 10% or less the percentage of patients treated within the appropriate time window, Despite various limitations, the concept of neuroprotection as potentially valuable adjunct therapy for acute ischemic stroke is still the subject of extensive research. lt is based on extention of the window for recanalization therapy or on prevention of neuronal death caused either by ischemic brain injury or by reperfusion injury after successful therapy. The main targets for decreasing or preventing reperfusion injury include decreasing reactive oxygen species, suppressing microglia, preventing hyperglycemia etc. ln the past decades, the efficacy and safety of numerous neuroprotective agents were shown in various animalstroke models, However, in clinicaltrials, promising pre-clinical studies have not been translated into positive outcomes. The combination of thrombolysis with pharmacological and non-pharmacological neuroprotective approaches, the clinical studies pertaining to neuroprotection, as well as the different preclinical neuroprotective therapies, their presumed mechanisms of action and their future applications in stroke patients will be discussed. Supported by grant uniri-biomed-l8-115 , , Molecular mechanrsms of ischemic brain damage and neuroprotection" to Jasenka Mrsic- Pelcic.

Acure cerebral ischemia ; Neuroprotection, Rat

nije evidentirano